1. Which people with diabetes are treated with a disposable, half‐unit insulin pen? A real‐world, retrospective, database study in Spain
- Author
-
F. Javier Ampudia‐Blasco, Natalia Duque, Esther Artime, Elena Caveda, Erik Spaepen, Silvia Díaz‐Cerezo, Miriam Rubio‐ deSantos, Daniel Callejo Velasco, and M. Pilar Bahíllo‐Curieses
- Subjects
diabetes mellitus, Type 1 ,diabetes mellitus, Type 2 ,insulin lispro ,retrospective study ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Abstract Introduction Insulin lispro 100 units/mL Jr KwikPen is the first prefilled, disposable, half‐unit insulin pen that delivers 0.5–30 units in increments of 0.5 units for the treatment of patients with diabetes. This study describes the profile of patients in Spain who initiated insulin therapy with Jr KwikPen in a real‐world setting. Methods This retrospective, observational study based on IQVIA's electronic medical records database included patients with Type 1 (T1D) or Type 2 (T2D) diabetes who initiated therapy with Jr KwikPen between May 2018 and December 2020. Sociodemographic, clinical, and treatment characteristics at treatment initiation were analysed descriptively. Results A total of 416 patients were included. The main characteristics of the T1D/T2D groups (N = 326/90), respectively were as follows: female sex, 61.7%/65.6%; mean age (standard deviation [SD]), 32.5 (20.7)/55.5 (16.6) years; body mass index, 20.9 (4.2)/25.2 (4.6) kg/m2 (N = 239/77); HbA1c, 7.8 (1.7)%/8.0 (1.5)% (N = 141/64); and presence of diabetes‐associated comorbidities, 27.9%/64.4%. Only 32.8% of patients with T1D were
- Published
- 2023
- Full Text
- View/download PDF